Related Experiment Videos
Biomarkers for breast cancer.
1Department of Surgery, University of Alabama at Birmingham and University of Alabama Hospital, Birmingham, AL, USA. samuel.beenken@ccc.uab.edu
Minerva Chirurgica
|July 30, 2002
Summary
This study categorizes molecular biomarkers for breast cancer, including risk, surrogate, prognostic, and predictive types. Understanding these biomarkers is crucial for developing advanced breast cancer diagnostics and treatments.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Breast cancer molecular biomarkers are diverse, encompassing risk, surrogate, prognostic, and predictive categories.
- These biomarkers play critical roles in cancer risk assessment, early detection, and treatment response evaluation.
Purpose of the Study:
- To provide a comprehensive overview of the different types of molecular biomarkers used in breast cancer research and clinical practice.
- To highlight candidate prognostic biomarkers and their potential in developing advanced diagnostic indices.
Main Methods:
- Review and categorization of existing literature on molecular biomarkers for breast cancer.
- Identification and discussion of specific candidate biomarkers, including proliferation indices, hormone receptors, oncogenes, apoptosis regulators, and signaling pathway proteins.
Main Results:
- Classification of biomarkers into risk, surrogate endpoint, prognostic, and predictive categories.
- Detailed listing of candidate prognostic biomarkers such as Ki-67, PCNA, ER, PR, c-erbB-2, TGF-a, EGFr, bcl-2, bax/bcl-2 ratio, p53, c-myc, TGF-b II receptor, retinoic acid receptor, and VEGF.
Conclusions:
- Molecular biomarker knowledge is expanding, paving the way for sophisticated prognostic indices.
- Future prognostic indices will likely integrate individual molecular biomarker data with clinical and pathological factors for improved breast cancer management.